Eleusis
At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop, and Delivery approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases.
Nasdaq: ELEU
IR Website: https://www.eleusisltd.com/news-views/
Headquarters: London, England
Content provided by Eleusis on 3/2/22.
TALK TO MANAGEMENT
The Eleusis management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Approach
At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop, and Delivery approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases.
Science
Psilocybin is an investigational drug that we believe could transform the treatment of depression. To fully realize the potential of psilocybin, however, we believe a new approach to its formulation is required- an approach targeting a consistent, controllable, and practical delivery of psilocybin’s active ingredient that could make it a mainstream treatment option for depression covered by insurance.
Care Delivery
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require
Investor Presentation
Recent News
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II
Jan 20, 2022
Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership
July 12, 2021
Eleusis Accelerates Psychedelic Drug Discovery and Development Team with Appointment of David Nichols, Ph.D., as Director of Molecular Pharmacology
Jan 11, 2021
Management Overview
Shlomi Raz
Chief Executive Officer
Shlomi is the founder and Chief Executive Officer of Eleusis. Since founding Eleusis in 2013, Shlomi has overseen the company’s corporate and clinical development efforts. Prior to founding Eleusis, Shlomi was a Managing Director at Goldman Sachs, and held a similar role at JPMorgan where he began his corporate career.
Shlomi holds an MA in psychology from New York University and a BS in finance from Georgetown University.
Rob Conley
SVP, Clinical Development
Rob Conley is the Senior Vice President for Clinical Development at Eleusis. He recently retired from Eli Lilly and Co. where he served as the Chief Science Officer from late phase Neuroscience. Prior to that he had a long academic career, first at the University of Pittsburgh and then at the University of Maryland School of Medicine. He remains an Adjunct Professor of Psychiatry and Psychopharmacology at Maryland.
Rob holds an MD from the University of Maryland School of Medicine and a BA from the Johns Hopkins University. He completed a Psychiatry residency at the University of Pittsburgh, where he served as the Chief Resident. Rob is also a Fellow of the American College of Neuropsychopharmacology.
Gene Ramirez
Chief Financial Officer
Gene is the Chief Financial Officer of Eleusis. Prior to Eleusis, Gene was a Founder of Technology and Digital Health Investment Banking Groups for a number of global financial services firms in which he has built industry-recognized businesses with sustainable and growing franchises domestically and internationally. Gene has been a trusted advisor to CEOs and Boards of Directors across venture and private equity backed companies, and advised a broad spectrum of growth companies on more than 90 initial public offerings, private financings, and mergers and acquisitions representing over $25 billion in transaction value. In addition, Gene has founded two healthcare software companies, one of which was sold to Oracle in 2002, and started his career at Robertson Stephens as an Equity Research Analyst.
Gene received an M.B.A. with a concentration in Entrepreneurship from the Franklin W. Olin Graduate School of Business at Babson College, and a B.A. in Economics with a specialization in Finance from the University of Texas at Austin.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Eleusis (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
